John Libbey Eurotext

European Journal of Dermatology

MENU

The burden of chronic spontaneous urticaria: unsatisfactory treatment and healthcare resource utilization in France (the ASSURE-CSU study) Volume 28, numéro 6, November-December 2018

Illustrations

  • Figure 1
  • Figure 2

Tableaux

Auteurs
1 CHU de Nice, University Côte d’Azur, France
2 CHU de Toulouse,
Hôpital Larrey,
Toulouse, France
3 CHU d’Angers,
Angers, France
4 CHRU de Lille,
Lille, France
5 Hospices civils de Lyon,
Claude-Bernard University,
Lyon, France
6 Novartis Pharmaceuticals Corporation,
East Hanover,
NJ, USA
7 RTI Heath Solutions,
Manchester, UK
8 RTI Health Solutions,
Research Triangle Park,
NC, USA
9 Novartis Pharma SAS,
Rueil-Malmaison,
France
10 Novartis Pharma AG,
Basel, Switzerland
* Reprints
  • Mots-clés : chronic spontaneous urticaria, chronic idiopathic urticaria, angioedema, health-related quality of life, health economics, observational study
  • DOI : 10.1684/ejd.2018.3446
  • Page(s) : 795-802
  • Année de parution : 2018

Background

Data on the clinical burden of chronic spontaneous urticaria (CSU) and economic consequences are lacking in France.